Education and Training
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Light-activated AU-011
- device: Laser Activation
Eligibility
Inclusion Criteria:
- Diagnosis of choroidal melanoma
Exclusion Criteria:
- Have known contraindications or sensitivities to the study drug
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mariana Nunez
650-497-7846
Not Recruiting